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ABSTRACT
Next-generation sequencing (NGS) can identify and validate new biomarkers of 
cancer onset, progression and therapy resistance. Substantial archives of formalin-
fixed, paraffin-embedded (FFPE) cancer samples from patients represent a rich 
resource for linking molecular signatures to clinical data. However, performing NGS 
on FFPE samples is limited by poor RNA purification methods. To address this hurdle, 
we developed an improved methodology for extracting high-quality RNA from FFPE 
samples. By briefly integrating a newly-designed micro-homogenizing (mH) tool with 
commercially available FFPE RNA extraction protocols, RNA recovery is increased by 
approximately 3-fold while maintaining standard A260/A280 ratios and RNA quality 
index (RQI) values. Furthermore, we demonstrate that the mH-purified FFPE RNAs 
are longer and of higher integrity. Previous studies have suggested that pancreatic 
ductal adenocarcinoma (PDAC) gene expression signatures vary significantly under in 
vitro versus in vivo and in vivo subcutaneous versus orthotopic conditions. By using 
our improved mH-based method, we were able to preserve established expression 
patterns of KRas-dependency genes within these three unique microenvironments. 
Finally, expression analysis of novel biomarkers in KRas mutant PDAC samples 
revealed that PEAK1 decreases and MST1R increases by over 100-fold in orthotopic 
versus subcutaneous microenvironments. Interestingly, however, only PEAK1 levels 
remain elevated in orthotopically grown KRas wild-type PDAC cells. These results 
demonstrate the critical nature of the orthotopic tumor microenvironment when 
evaluating the clinical relevance of new biomarkers in cells or patient-derived samples. 
Furthermore, this new mH-based FFPE RNA extraction method has the potential to 
enhance and expand future FFPE-RNA-NGS cancer biomarker studies.
INTRODUCTION
Next-Generation Sequencing (NGS), such 
as RNA-seq or whole-genome analysis, of patient-
derived tumor tissue in combination with state-of-the 
art bioinformatics holds great potential to improve 
disease outcomes by identifying novel biomarkers 
of cancer onset, progression and therapy resistance 
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[1–3]. Among the advantages of NGS over other 
technologies is the ability to perform high-resolution 
transcriptome monitoring to identify isoform variations, 
outlier expression patterns and expression signatures 
of low expressing genes or long noncoding RNAs [4]. 
Importantly, these data can help to differentiate between 
unique molecular subtypes of various malignancies 
for the purpose of guiding diagnosis, prognosis and 
therapeutic interventions [5, 6].
To succeed in this endeavor, it is essential to 
correlate clinical and NGS data from a wide sampling 
of patient tumors that take into account a physiological 
tumor microenvironment. However, understanding 
the effects of the tumor microenvironment on gene 
expression and, in particular, cancer-cell biomarker 
profiles is hindered by the fact that researchers have 
limited access to fresh tumor tissue, which harbor good-
quality and easily-accessible nucleic acid material - these 
samples are not routinely obtained in hospitals due to 
the logistical challenges of collecting, processing and 
banking fresh-frozen tissue [7]. Formalin-fixed paraffin-
embedded (FFPE) samples, however, are routinely 
collected for pathology analysis, and substantial archives 
of FFPE tissues from all types of malignancies have been 
established and linked to clinical data [8]. Yet, it remains 
extremely difficult to recover sufficient high-quality RNA 
from these FFPE samples due to formalin-induced cross-
linking and degradation as well as the requirement for 
large amounts of the FFPE samples and time consuming 
methods for RNA extraction [9, 10]. Thus, a significant 
need exists for the development of more efficient methods 
to recover high-quality nucleic acid material from FFPE 
samples without sacrificing large amounts of these 
valuable samples [8].
Members of our team have previously developed 
disruption and nucleic acid isolation technologies that 
have proven useful to the biomedical research and 
clinical communities [11, 12]. We hypothesized that the 
microHomogenizer™ (mH) device could significantly 
disrupt FFPE tissue to liberate more high-quality RNA 
material and increase the efficiency of RNA purification 
from FFPE samples using standard kits. In the present 
study, the combination of our mH technology with 
the Qiagen FFPE RNA extraction kit has significantly 
improved RNA quality and yield from pancreatic ductal 
adenocarcinoma (PDAC) patient and cell line derived 
xenograft FFPE samples. We have focused this new RNA 
extraction technology on PDAC, since this recalcitrant 
disease is in need of new biomarkers for early diagnosis 
[13–15]. We have validated the mH technology on 
FFPE specimens by demonstrating that gene expression 
signatures obtained for key biomarker genes agree with 
those that have been previously published using freshly-
frozen specimens [16]. The method further enabled us 
to evaluate the microenvironmental and KRas mutant 
effects on biomarker expression in PDAC xenograft 
mouse models; most importantly, showing very large 
differences between patient tumors growing at orthotopic 
(e.g., patient-derived orthotopic xenografts [PDOX]) and 
subcutaneous sites. Such methodological improvements 
and translational insights will certainly aid researchers and 
clinicians in efforts to diagnose and treat PDAC, as well as 
other malignancies, using NGS technology.
RESULTS
The mH increases RNA yield from PDAC FFPE 
samples
Figure 1A shows an example of formalin-fixed, 
paraffin-embedded (FFPE) samples used in oncology 
and pathology for hematoxylin and eosin (H&E) staining 
as well as immunohistochemistry (IHC). Importantly, 
FFPE samples also hold great promise for biomarker 
identification since there is a surplus of these samples 
linked to clinical data. However, a major hurdle in 
utilizing these samples for next-generation sequencing 
(NGS) or other -omics methods is that the RNA 
material within FFPE samples is commonly degraded 
and retrieving sufficient high-quality material for such 
methods is prohibitive. To address this hurdle, we 
collaborated with Claremont BioSolutions and applied 
their microHomogenizerTM (mH) device to liberate more 
intact, high-quality RNA during this standard FFPE 
purification method. FFPE samples were generated 
from palpable tumors grown as either subcutaneous 
or orthotopic xenografts of BxPC3 (KRas wild type 
PDAC line), FG (KRas mutant PDAC line) or MDA-
AC2 (primary patient PDAC tissue) samples in nude 
(nu/nu) mice. Figure 1B shows representative H&E 
images of each tumor sample indicating the tumor 
morphology. Notably, orthotopic xenografting yielded 
tumors with more stromal infiltration, indicative of a 
more physiologically relevant tumor microenvironment 
(TME). RNA yield and purity were measured for 
PDAC FFPE samples processed using the Qiagen 
FFPE RNA purification kit according the manufacturer 
recommendations, with or without the mH. While the 
Qiagen kit is typically used without any sample disruption 
method, we adapted the method by adding two steps of 
two-minute sample homogenization using the mH (at 
6 volts). Once RNA was extracted from each sample, 
three different devices were used for its analysis (Figure 
1C and 1D). A NanoDrop 2000c was used to quantify 
both the concentration (ng/uL) and purity (A260/A280 
ratio) of RNA extracted (Figure 1C and 1B). A ratio of 
~2.0 is generally accepted as “pure” for RNA (Figure 
1B). A Qubit and Experion bioanalyzer were also used 
to quantify RNA concentration (ng/uL) (Figure 2A). 
Notably, RNA purified using our mH-based method 
consistently yielded higher concentrations of RNA 
(Figure 2C) and RNA of higher purity (Figure 1D).
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Figure 1: A. FFPE samples are usually used for hematoxylin and eosin (H&E) and/or immunohistochemistry (IHC) stains. To overcome 
hurdles associated with gene expression analyses of tissue in FFPE samples, we show that the mH can increase the purification of high-
quality RNA for downstream applications. B. H&E staining of the four xenograft FFPE samples (BxPC3 [B] and FG [F]) or patient (MDA-
AC2 [M]) xenografts (S = subcutaneous, O = orthotopic). C. Nucleic acid (RNA) concentrations (ng/uL) for the four FFPE samples of 
PDAC using either the standard Qiagen FFPE RNA extraction (-mH) or our mH-modified protocol (+mH). Measurements were made using 
Nanodrop, Qubit and Experion Bioanalyzer assays. D. Average +/- standard error mean (SEM) RNA 260/280 ratios for the same samples 
described in (A). *, **, *** indicate student t-test p values < 0.05, 0.01 and 0.001, respectively.
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The mH increases RNA integrity & length from 
PDAC FFPE samples
A major hurdle in using FFPE samples as an 
upstream source for NGS-based biomarker research is 
the poor quality of RNA that results from the extraction 
process [9, 10]. Since our mH-based method was able 
to liberate increasing amounts of RNA from the FFPE 
samples, we further reasoned that the mH-purified RNA 
may contain longer RNAs of increasing integrity. To test 
this hypothesis, we analyzed FFPE RNA extracted with 
and without the mH using an Experion bioanalyzer. As 
shown in Figure 2A, electropherograms and gel separation 
of the FFPE RNA purified using the mH-based method 
contains significantly longer RNA molecules with bands 
indicating RNA lengths of up to 6000 bases. We further 
evaluated the quality of these longer RNA molecules using 
qPCR to detect intracellular β-actin with primer variants 
designed to produce various amplicon sizes (i.e., 107, 181 
and 493 bps). Notably, the mH-purified RNA produces 
higher β-actin RQ values consistently for the longer 
amplicon primers (Figure 2B). These results suggest that 
our improved mH-based FFPE RNA extraction protocol 
significantly increases RNA yield, purity and integrity.
mH-mediated RNA purification maintains 
tumor microenvironment (TME)-specific gene 
expression profiles
The importance of the TME in the initiation and 
progression of cancer is well established [16–19]. We 
plotted normalized gene expression values reported by 
Nakamura et al. using fresh-frozen specimens of FG 
PDAC cells grown in vitro or in vivo as orthotopic or 
subcutaneous xenografts (Figure 4A) [16, 19]. For our 
analyses, we chose to focus on the expression pattern for 
Figure 2: A. Overlay of representative Experion-generated electropherograms and gels for total extracted FFPE RNA from either the -mH 
or +mH RNA extraction methods. L, - and + in the gels indicates lanes for the ladder, -mH and +mH sample preparation methods. B. RNA 
extracted from FFPE tumor samples using these two methods was reverse transcribed to cDNA and analyzed by qPCR in triplicate using 
βactin-specific primers that generate increasing length amplicons. βactin Ct values were normalized relative to the HPRT1 and POLR2A 
house-keeping genes and plotted as relative quantification (RQ) fold change compared to the FFPE samples processed without the mH-
based method. * indicates a Student’s t-test p value < 0.05.
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three genes that were previously reported to be part of a 
KRas-dependency signature in PDAC and lung cancer 
[20]. Notably, maximal expression for the SYK and CDH1 
genes was observed by Nakamura and colleagues when 
the FG cells were propagated in vivo as subcutaneous 
xenografts, while they reported maximal expression for 
ITGB6 when the cells were cultured in vitro (Figure 3A). 
We then harvested RNA from FG cells grown in vitro or 
in vivo as orthotopic xenograft tumors using either the 
Qiagen RNA or FFPE RNA purification kits without the 
use of the mH. As shown in Figure 3B, the gene expression 
trend for CDH1 in FG cells grown in vitro versus as an 
orthotopic xenograft matches that from Nakamura and 
colleagues. However, these trends for both the SYK and 
ITGB6 genes are opposite to those reported by Nakamura 
et al. In contrast, when we used our mH-based method to 
purify the RNA from FFPE samples of FG cells grown in 
vivo as subcutaneous vs. orthotopic tumors, the trends in 
expression for these three genes match those previously 
reported by Nakamura et al. using fresh-frozen material 
from these three microenvironments (Figure 3C). 
These results, together with the data presented above, 
demonstrate that using the mH during RNA purification 
from FFPE tumor samples enables gene expression studies 
that more faithfully recapitulate the gene expression 
patterns generated from fresh-frozen tissue.
Figure 3: A. Previously published expression patterns for ITGB6, SYK and CDH1 genes (Nakamura et al.) in FG cells grown under 2D 
in vitro, subcutaneous in vivo and orthotopic in vivo microenvironment conditions. RNA was processed from fresh/frozen samples. B and 
C. qPCR analysis for these same three genes in RNA extracts from FG cells grown in vitro or FFPE samples of FG cell xenografts. RNA 
was isolated using the standard Qiagen FFPE RNA kit protocol (B) or our mH-modified protocol (C). Relative quantification (RQ) values 
for gene expression were normalized to house-keeping genes (GAPDH and/or POLR2A) and calculated relative to gene expression levels 
in cells grown in vitro.
Oncotarget5890www.impactjournals.com/oncotarget
Analysis of TME effects on PDAC biomarkers in 
KRasG12D vs. KRasWT Cells
Not only are activating Ras mutations the most 
common oncogenic alteration among solid cancers, it is 
well established that mutations that constitutively activate 
KRas are an early event in the pathogenesis of nearly all 
pancreatic cancers [13, 14, 18]. Nonetheless, some PDACs 
do not contain this oncogenic mutation. Thus, it is relevant 
to investigate how the microenvironment changes gene 
expression patterns for key biomarkers in KRas mutant 
and KRas wild type PDAC models. We harvested RNA 
from FG (KRasG12D mutant) and BxPC3 (KRas wild 
type) PDAC cells grown in vitro or as in vivo xenografts 
using our mH-based extraction method of RNA from the 
FFPE tumor samples. We subsequently analyzed gene 
expression for the genes shown in Figure 3 as well as 
MST1R and PEAK1. MST1R (or the RON receptor) was 
previously reported by Singh and colleagues to be part of 
a KRas dependency gene signature [20] and can promote 
resistance to the chemotherapy drug gemcitabine [21]. We 
have previously reported that PEAK1 kinase is essential 
for the initiation and progression of pancreatic cancer 
[22–24]. As shown in Figure 4A, with the exception of 
ITGB6, the expression for these other biomarker genes 
increases when the KRas mutant FG cells are propagated 
in the orthotopic pancreatic microenvironment relative to 
in vitro. Notably, PEAK1 and MST1R expression levels 
were decreased and increased, respectively, by over 100-
fold in KRas mutant PDAC cells xenografted into the 
orthotopic microenvironment relative to the subcutaneous 
microenvironment (Figure 4A). In contrast, only PEAK1 
expression levels increase in the KRas wild type BxPC3 
cells when they are grown in vivo (Figure 4B).
DISCUSSION
In conclusion, we have established a new method for 
purifying RNA from FFPE tumor samples that liberates 
more high quality RNA for downstream applications. This 
method has been validated using qPCR to compare gene 
expression of important PDAC biomarkers previously 
published from fresh-frozen samples with those generated 
from our FFPE samples for the same cells and same 
microenvironments (Figure 3). Importantly, incorporating 
the Claremont BioSolutions’ mH into commercially 
available FFPE RNA purification protocols can improve 
RNA yield, purity and integrity yielding more accurate 
results in gene expression studies (Figures 1 and 2). 
Furthermore, we predict that this will have an integral 
positive impact on future NGS studies, since unlike qPCR 
or microarray technology, the accuracy of this technology 
requires much more high quality RNA in the starting 
material.
Additionally, we have demonstrated that MST1R 
and PEAK1, two well-established regulators of PDAC 
progression and therapy resistance [21–25], may fulfill 
distinct roles during the progression of KRas mutant and 
KRas wild type PDAC. While PEAK1 is upregulated 
in both genetic backgrounds within PDAC cells under 
physiologically relevant tumor microenvironment 
conditions (i.e., the orthotopic site in nude mice), MST1R 
is only upregulated in KRas mutant cells implanted at this 
site (Figure 5). While additional work is needed to assess 
the functional relevance of both PEAK1 and MST1R in 
the context of KRas wild type cancers, these data predict 
that PEAK1 may be a more potent driver of initiation 
and progression under these wild type KRas conditions. 
However, while our qPCR primers were designed to 
Figure 4: A and B. qPCR analysis of ITGB6, SYK, CDH1, PEAK1 and MST1R in FG (A, KRas mutant G12D line) or BxPC3 (B, KRas 
wild type line) PDAC cells grown under the indicated microenvironmental conditions. All RNA was extracted using our mH-modified 
Qiagen FFPE kit protocol and relative quantification (RQ) values for gene expression were normalized to house-keeping genes (GAPDH 
and/or POLR2A).
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detect all gene product isoforms, it will be important 
for future sequencing studies to evaluate the isoform-
specific expression patterns for these genes as isoform 
differences for the MST1R gene have been implicated in 
its transformative potential [25]. We predict that this new 
mH-based RNA extraction method can now be applied 
to evaluate tumor-specific factors that can regulate the 
splicing and tumorigenic potential for MST1R and other 
genes associated with PDAC. Our data further emphasize 
the importance of studying PDAC as well as other cancer 
types as patient-derived orthotopic xenografts (PDOX) 
rather than as subcutaneous xenografts in nude mouse 
models [26–35]. 
Previously developed concepts and strategies of 
highly selective tumor targeting can now take advantage 
of these new methods of biomarker measurement using 
the mH-based RNA extraction method described here 
and NGS technology to identify differences between the 
microenvironment of normal and tumor tissue [36–41].
MATERIALS AND METHODS
Cell culture
BxPC3 and FG cells were cultured in complete 
Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 10% fetal bovine serum and antibiotics. 
Cells were maintained at 5% CO2 and 37°C.
Animal care
Athymic nu/nu nude mice between 4 and 6 weeks of 
age were maintained in a barrier facility on high efficiency 
particulate air (HEPA)-filtered racks. The animals were 
fed with autoclaved laboratory rodent diet (Teckland LM-
485; Western Research Products, Orange, CA). All animal 
studies were approved by the UCSD Institutional Animal 
Care and Use Committee and conducted in accordance 
with the principles and procedures outlined in the NIH 
Guide for the Care and Use of Animals.
Sourcing of human tumor tissue
The tumor tissue from the MDA-AC2 sample was 
obtained and initially xenografted subcutaneously at the 
M.D. Andersen Cancer Center [29–35] in accordance 
with Institutional Review Board (IRB) approval. Tissue 
was obtained at the time of tumor resection. Excess fresh 
tumor was used for immediate xenografting into mice. All 
surgically-resected tumor fragments were stored in sterile 
specimen cups and expeditiously transported from the 
operating room to the laboratory on ice.
Xenografting
MDA-AC-2 tumors growing subcutaneously were 
harvested and implanted orthotopically at AntiCancer, 
Inc., in accordance with the principles and procedures 
outlined in the NIH Guide for the Care and Use of Animals 
under Assurance number A3873-01. Alternatively, PDAC 
cell cultures were prepared at 1×106 cells/20 μl for 
antibiotic-free DMEM for implantation. Nu/nu mice were 
anesthetized with intraperitoneal injection of ketamine 
xylazine cocktail (60 mg/kg: 10 mg/kg). They were then 
placed in the supine position on a warm pad to maintain 
body temperature. Once mice were sedated, the abdominal 
wall was cleansed with 70 alcohol and betadine. For 
orthotopic xenografting, a 1-2 cm midline incision was 
made in the left lateral flank through the skin, fascia, and 
peritoneum, and the tail of the pancreas was exposed. For 
patient-derived tissue fragments, surgical sutures (6-0 
silk) were used to implant tumor fragments (1 mm3) onto 
the pancreas [26, 27]. For PDAC cell suspensions, 20 μl 
was injected directly into the pancreas. The pancreas was 
then returned to the abdomen, and the peritoneum and 
skin were closed using 6-0 Polysorb surgical suture. For 
subcutaneous xenografting, 100 μl of the cell suspension 
was injected into each flank of the mice. Mice were 
monitored daily for 5 consecutive days after surgery 
with particular attention paid to animal distress, wound 
dehiscence, and signs of infection. Thereafter, they were 
examined daily. Tumor progression was also evaluated 
by ultrasound every 3-4 weeks. Animals were euthanized 
based on either tumor volume (threshold 2500 mm3) as 
determined by ultrasound or clinical status during the 
observation period as specified in our IACUC-approved 
protocol. Tumors were harvested and fixed in 10% 
formalin for 16 hours prior to exchanging the formalin for 
95% ethanol and subsequent processing and analysis.
Sample processing
Formalin-fixed tissue specimens were processed for 
paraffin embedding and sectioning at the UCLA pathology 
core and returned to the research team as paraffin blocks, 
H&E stained sections and unstained sections.
RNA extraction
FFPE samples were weighed out to approximately 
10mg each and then the Qiagen FFPE RNA extraction 
kit was used either with or without the Claremont 
Biosolutions’ microHomogenizer™ (mH) device. For 
mH-modified protocol, the microHomogenizer was used 
twice during the deparaffinization step for 2-minute cycles 
at power of 6 volts. The remainder of the protocol was 
followed as directed by the kit instruction manual. RNA 
harvested from cells propagated in vitro was purified using 
the standard Qiagen RNA purification kit.
RNA quantification
RNA concentrations were quantified using three 
methods: NanoDrop, Qubit, and Experion. For NanoDrop 
Oncotarget5892www.impactjournals.com/oncotarget
runs, the instrument was blanked with nuclease-free water 
and samples were analyzed to determine nucleic acid 
concentrations in ng/uL as well as 260/280 ratios. For Qubit 
runs, the instrument was calibrated using Qubit® RNA 
Broad-Range assay kit by Life Technologies. Buffer (198 μL) 
was used with 1 μL of dye and 1 μL of sample. Samples were 
analyzed to determine nucleic acid concentrations in ng/μL. 
For Experion runs, the Experion™ RNA StdSens Analysis 
Kit by Bio-Rad Laboratories was used. RNA StdSens Chip 
was prepared according to the manufaturer’s protocol.
Reverse transcription and qPCR
The Fermentas Maxima Universal Strand cDNA kit 
was used to synthesize cDNA using 100ng of template and 
both oligo(dT) and random hexamer primers according 
the manufacturer’s protocol. cDNA concentrations were 
determined by NanoDrop and then diluted to 22.5ng/mL to 
perform qPCR. Primers were purchased from Intergrated 
DNA technologies and used at a concentration of 10nmol/
mL. 8.75μL of nuclease-free water was mixed with 2.5μL of 
diluted cDNA, 1.25μL of gene-specific primer, and 12.5μL of 
Thermo Scientific Maxima SYBR Green/ROX qPCR Master 
Mix. Samples were run on an ABI 7300 instrument. Average 
ΔΔCT values from three independent qPCR experiments 
were used to calculate average relative quantification units 
and plotted as fold change relative to the appropriate control.
PCR primers
ACTB-493 – AGCCATGTACGTTGCTATCC/
GTACAGGTCTTTGCGGATGT
ACTB-181 – GGAAATCGTGCGTGACATTAAG/
GAAGGAAGGCTGGAAGAGTG
ACTB-107 – GGACCTGACTGACTACCTCAT/
CGTAGCACAGCTTCTCCTTAAT
CDH1 – GTCACTTCAGACTCCAGCCC/
AAATTCACTCTGCCCAGGACG
ITGB6 – CAAGTTGAGTCCTTCAGTGTCT/
GACTCCGGAAACATTCTCCAG
MST1R – GTCTGCCTCCCAGCATTG/
TTGACCCTTTTGACCTTACCC
SYK – TCTTGTCTTTGTCGATGCGAT/
CTCGGGAAGAATCTGAGCAAA
PEAK1 – GCTGAGATTCTTTAGCTTTGCTC/
GACTTCAGGCTAACCAGTGAC
HPRT1 – GCGATGTCAATAGGACTCCAG/
TTGTTGTAGGATATGCCCTTGA
POLAR2A – TCGTCTCTGGGTATTTGATGC/
CAGTTCGGAGTCCTGAGTC
GAPDH – TGTAGTTGAGGTCAATGAAGGG/
ACATCGCTCAGACACCATG
Statistical analysis
All quantified data were plotted and analyzed in 
GraphPad Prism 5.0 with using a Student’s t-test. Data are 
representative of at least 3 independent experiments and 
are reported as replicate averages ± SEM, unless otherwise 
indicated.
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